We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Teoxane, which holds a 6.2% stake in Revance and is a key customer of the Nashville, Tenn., company, had proposed buying the rest of the company for $3.60 a share after Crown reduced its planned ...

According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion and the Middle East and ...

Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...

Explore our top 10 DJIA stocks picks with expert analysis, market trends, and investment insights to help you make informed ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

FRANKFURT (Reuters) - The euro zone economy stagnated last quarter as worried consumers zipped up their purses, adding to fears that a long-predicted recovery could be further delayed, Eurostat data ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...